Skip to main content

NCI PQ logo

Search form

Center for Strategic Scientific Initiatives

 logo Center for Strategic Scientific Initiatives
 logo
  • About PQs
    • History
    • Mission
    • Awarded Grants
    • Contact Us
  • Current RFAs and PQs
  • Expired RFAs and PQs
    • 2017/2018 Archived RFAs and PQs
    • 2015 Archived RFAs and PQs
    • 2013 Archived RFAs and PQs
    • 2012 Archived RFAs and PQs
    • 2011 Archived RFAs and PQs

You are here

  • Home
  • About PQs
  • Awarded Grants

Awarded Grants

Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

New FY2016 awards will be posted as they are issued.

Grant Yearsort ascending Grant Award Type Project Number Grant PI Name Title
2017 R21 CA231000-01A1 KENNEDY, DANIEL ROBERT (contact); ZWICKER, JEFFREY Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosis
2017 R01 CA231267-01 FEHRENBACHER, JILL C (contact); KELLEY, MARK R (PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
2017 R01 CA227493-01 MARPLES, BRIAN (contact); FORNONI, ALESSIA (PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity
2017 R01 CA219637-01A1 DAMAJ, M IMAD (contact); GEWIRTZ, DAVID A (PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
2017 R01 CA219829-01A1 ZHANG, ZHENG GANG Exosomes and platinum-induced peripheral neuropathy
2017 R01 CA242158-01 JANG, MI-HYEON PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain
2017 R01 CA227517-01A1 TANIGUCHI, CULLEN MITSUO Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer
2017 R01 CA220002-01A1 BURRIDGE, PAUL W (contact); STRANGER, BARBARA E Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
2017 R21 CA231131-01A1 CARSON, JAMES A (PQ 12) The Regulation of Physical Function and Skeletal Muscle Metabolic Signaling After Cessation of 5-Fluorouracil Treatment
2017 R01 CA227064-01 KAVELAARS, ANNEMIEKE (contact); HEIJNEN, COBI J PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain
2017 R01 CA238946-01 LUSTBERG, MARYAM B (contact); HU, SHUIYING Prevention of paclitaxel-induced peripheral neuropathy with nilotinib
2017 R01 CA231219-01 ARONSON, WILLIAM J (contact); COHEN, PINCHAS Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
2017 R01 CA227479-01 SIMONE, NICOLE L (11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
2017 R01 CA231239-01A1 ACHARYYA, SWARNALI Modulating dietary zinc to prevent cachexia and improve survival in cancer
2017 R21 CA238953-01 VISWANATHAN, SARASWATHI (contact); RACHAGANI, SATYANARAYANA Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy
2017 R21 CA242270-01 KAISER, PETER Methionine Dependency of Cancer
2017 R21 CA231255-01 ROSENBERG, DANIEL WILLIAM (PQ11) Dietary strategies to enhance FOLFOX cancer therapies
2017 R01 CA227230-01A1 CHEN, SHIUAN (contact); LAU, CLAYTON; TWARDOWSKI, PRZEMYSLAW WIKTOR (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research
2017 R21 CA227528-01 WEICHSELBAUM, RALPH R (PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
2017 R01 CA219896-01A1 WARGO, JENNIFER A (PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
2017 R01 CA219871-01A1 FACCIABENE, ANDREA (contact); KOUMENIS, CONSTANTINOS (PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
2017 R21 CA231273-01A1 WEICHSELBAUM, RALPH R Microbiota and the anti-tumor action of anti-CD47 immunomodulation.
2017 R21 CA227232-01 TURNBAUGH, PETER JAMES (contact); ATREYA, CHLOE E (PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
2017 R01 CA231303-01A1 KOH, ANDREW Y (contact); HOMSI, JADE ; PASARE, CHANDRASHEKHAR Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
2017 R01 CA242305-01 JAMES, LINDSEY INGERMAN Discovery of first-in-class nsd2 degraders for cancer therapy
2017 R01 CA238570-01 CREWS, CRAIG M Developing Tumor-specific PROTACs
2017 R01 CA230854-01 JIN, JIAN (contact); PARSONS, RAMON E (PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
2017 R01 CA242003-01 ZHOU, DAOHONG (contact); TREVINO, JOSE G; ZHENG, GUANGRONG Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer
2017 R01 CA231295-01 OSMAN, IMAN (contact); WEBER, JEFFREY S (PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
2017 R01 CA227466-01 ZIV, ELAD (8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
2017 R21 CA231277-01A1 MOR, ADAM (PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade
2017 R01 CA231291-01 WELLSTEIN, ANTON (contact); ATKINS, MICHAEL BENJAMIN (PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
2017 R01 CA227481-01A1 BALKO, JUSTIN M (contact); JOHNSON, DOUGLAS B (PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
2017 R21 CA231280-01A1 FANTL, WENDY JANE (contact); LEPPERT, JOHN THOMAS (PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy
2017 R01 CA231226-01A1 BUCKNER, JANE HOYT (contact); CHOW, LAURA ; LINSLEY, PETER S; WAMBRE, ERIC Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
2017 R01 CA227505-01 KIRCHHOFF, TOMAS (contact); WEBER, JEFFREY S (8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
2017 R01 CA238471-01 DHODAPKAR, KAVITA (contact); SANZ, IGNACIO E B cells in autoimmunity following checkpoint blockade therapy
2017 R01 CA238998-01 WEIDHAAS, JOANNE B Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
2017 R01 CA227473-01 HEROLD, KEVAN C (contact); KLUGER, HARRIET M (8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
2017 R21 CA231252-01A1 ASTSATUROV, IGOR (contact); CUKIERMAN, EDNA Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells
2017 R01 CA242226-01 ROGERS, GREGORY CHARLES (contact); CRESS, ANNE E Centrosome instability as a mechanism to promote localized prostate cancer
2017 R21 CA231269-01A1 LUSK, CHARLES PATRICK (contact); KING, MEGAN C Leveraging cancer-specific defects in nuclear integrity to inform novel synthetic lethal strategies
2017 R01 CA231300-01A1 BIVONA, TREVER G (contact); HUANG, BO (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules
2017 R21 CA227381-01 GADDAMEEDHI, SHOBHAN Chronotherapy as a Strategy to Attenuate Toxicity Associated with Cisplatin and Radiation Treatment for Triple-Negative Breast Cancer
2017 R01 CA230848-01 FU, LONING NONE (contact); MOORE, DAVID D (PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
2017 R21 CA227379-01 HONG, CHRISTIAN I (PQ6) Roles of circadian rhythms in tumor development
2017 R01 CA231321-01A1 BURCH, JAMES Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk
2017 R21 CA227375-01 REPASKY, ELIZABETH A (contact); ANTOCH, MARINA (PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
2017 R01 CA231122-01A1 HELLER, H CRAIG (#6) A novel animal model for determining the role of circadian timing in breast cancer development
2017 R01 CA238988-01 FU, LONING NONE (contact); MOORE, DAVID D Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • next ›
  • last »

About PQs

  • History
  • Mission
  • Awarded Grants
  • Contact Us
Contact Us


National Cancer Institute at the National Institutes of Health


  • NCI Home
  • Provocative Questions Home
  • Contact Us
  • Policies
  • Accessibility
  • Disclaimer
  • Viewing Files
  • FOIA

  • U.S. Department of Health and Human Services
  • National Institutes of Health
  • National Cancer Institute
  • USA.gov

NIH… Turning Discovery Into Health®